【摘要】 目的观察核苷类抗病毒药物治疗乙肝肝硬化患者的近期疗效及安全性。方法将172例乙肝肝硬化患者按照队列研究法分为治疗组和对照组,每组86例。对照组接受常规治疗,治疗组在对照组基础上加用核苷类抗病毒药物治疗,比较2组患者的近期疗效及并发症发生情况。结果治疗组患者谷草转氨酶(AST)、谷丙转氨酶(ALT)及总胆红素(TBiL)水平显著低于对照组,而白蛋白(Alb)及胆碱酯酶(ChE)水平显著高于对照组,差异有统计学意义;治疗组患者乙型肝炎病毒(HBV)DNA和乙型肝炎e抗原(HBeAg)转阴率,以及HBV DNA下降幅度均显著高于对照组,而自发性腹膜炎发生率显著低于对照组,差异均有统计学意义。结论核苷类抗病毒药物可有效改善乙肝肝硬化患者的肝功能,抑制HBV病毒复制,促使HBeAg转阴。更多还原

【Abstract】 Objective To observe the short term effect and safety of nucleoside antiviral drugs for treating patients with hepatitis B liver cirrhosis.Methods One hundred and seventy two patients with hepatitisB liver cirrhosiswere divided into treatment group and control group based on cohort study method,86 cases in each group.The patients in the control group were given routine treatment,while those in the treatment group were added nucleoside antiviral drugs based on the treatment of the control group.The short term effect and occurrence of complications were compared in both groups.Results The levelsof aspartateaminotransferase(AST),alanine aminotransferase(ALT)and total bilirubin(TBiL)in patients of the treatment group were significantly lower than those in the control group,while levels of albumin(Alb)and cholinesterase(ChE)markedly higher than the control group,and the differences showed statistical significance.The negative conversion ratiosof hepatitis B virus(HBV)DNA and hepatitis B e antigen(HBeAg)as well as the decreased range of HBV DNA in patients of the treatment group were all notably higher than those in the control group,whereas the incidence of spontaneous peritonitis significantly lower than the control group,and all the differences showed statistical significance.Conclusion In the treatment of hepatitis B liver cirrhosis,nucleoside antiviral drugs can effectively ameliorate the liver function,inhibit HBV virus replication and promote HBeAg to convert into negative.更多还原